Key Points
- Total revenue fell short of analysts' expectations.
- Adjusted EPS of $7.88 beat analyst estimates by 9%.
- The company raised its full-year EPS guidance.
McKesson Corporation (MCK -0.71%), a healthcare services and information technology company, released its fiscal 2025 first quarter results on Aug. 7. McKesson reported revenue of $79.28 billion, which missed analysts' consensus estimate of $82.53 billion. However, the company posted an adjusted earnings per share () of $7.88, significantly surpassing the analyst forecast of $7.21. This reflects the company's effective cost management and operational improvements during the quarter.
Understanding McKesson Corporation
| Metric | FY25 Q1 | Analyst Estimate | FY24 Q1 | YoY Change |
|---|---|---|---|---|
| Revenue (in billions) | $79.28 | $82.53 | $74.48 | 6% |
| Net Income (in millions) | $915 | N/A | $958 | -4% |
| Adjusted earnings per share | $7.88 | $7.21 | $7.27 | 8% |
| GAAP earnings per share | $7.00 | N/A | $7.02 | -0.28% |
| Source: Analyst estimates for the quarter provided by FactSet. |
McKesson operates in the , providing distribution and logistics services for pharmaceuticals, medical supplies, and technology solutions. The business is divided into four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
Recently, McKesson has emphasized investments in technology and automation to drive efficiency and growth. The company also continues to work on regulatory compliance and managing revenue concentration among its top customers, which includes CVS Health.
Quarterly Highlights
During the quarter, McKesson saw varying performance across its segments. The U.S. Pharmaceutical segment reported revenue of $71.7 billion, a 7% increase compared to the previous year, driven by higher prescription volumes and specialty products. Adjusted operating profit for this segment also grew by 6% to $815 million.
The Prescription Technology Solutions segment remained flat with revenue at $1.2 billion, while the adjusted operating profit was stable at $223 million. The Medical-Surgical Solutions segment saw a slight revenue increase of 1% to $2.6 billion but experienced a notable decline of 15% in adjusted operating profit to $200 million due to shifting demand and lower volumes.
The International segment performed well with a 6% revenue increase to $3.7 billion, driven by enhanced distribution in Canada. Adjusted operating profit also rose by 13% to $102 million in this segment.
Despite these growth areas, McKesson's net income declined from $958 million to $915 million, reflecting a 4% decrease. This decline was influenced by increased regulatory expenses and changes in other income.
Looking Ahead
McKesson has raised its full-year adjusted EPS guidance to a range of $31.75 to $32.55, up from the previous range of $31.25 to $32.05. This outlook suggests confidence in its cost management strategies and operational efficiencies moving forward.
Investors should monitor McKesson's technology investments and their impact on operational efficiency. Additionally, keeping an eye on regulatory compliance and the concentration of revenue among top customers will be critical. Notably, the company's continued efforts in strategic initiatives like dividends and share repurchases will also be relevant to follow.
